Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results : (48) Arrow Down
Filter Results : (48) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (112,695)
    • Faculty Publications  (48)

    Show Results For

    • All HBS Web  (112,695)
      • Faculty Publications  (48)

      Chandra, Amitabh Remove Chandra, Amitabh →

      Page 1 of 48 Results →
      • July 2023
      • Supplement

      Biogen and the Aduhelm Melee

      By: Amitabh Chandra and Lauren Gunasti
      This spreadsheet supplement corresponds to Exhibit 17 (Change in Biogen Valuation from Aducanumab Approval) from Case 623-046 "Biogen and the Aduhelm Melee."  View Details
      Citation
      Purchase
      Related
      Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Spreadsheet Supplement 624-702, July 2023.
      • June 2023
      • Case

      Biogen and the Aduhelm Melee

      By: Amitabh Chandra and Lauren Gunasti
      Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process. This case...  View Details
      Citation
      Educators
      Related
      Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023.
      • June 2023
      • Case

      Ishani Therapeutics: Valuing a Deal

      By: Amitabh Chandra and Sumon Mazumdar
      Citation
      Educators
      Purchase
      Related
      Chandra, Amitabh, and Sumon Mazumdar. "Ishani Therapeutics: Valuing a Deal." Harvard Business School Case 623-090, June 2023.
      • June 2023
      • Supplement

      Ishani Therapeutics: Valuing a Deal (Instructor Spreadsheet Supplement)

      By: Amitabh Chandra and Sumon Mazumdar
      Citation
      Purchase
      Related
      Chandra, Amitabh, and Sumon Mazumdar. "Ishani Therapeutics: Valuing a Deal (Instructor Spreadsheet Supplement)." Harvard Business School Spreadsheet Supplement 623-716, June 2023.
      • June 2023
      • Supplement

      Ishani Therapeutics: Valuing a Deal (Student Spreadsheet Supplement)

      By: Amitabh Chandra and Sumon Mazumdar
      Citation
      Purchase
      Related
      Chandra, Amitabh, and Sumon Mazumdar. "Ishani Therapeutics: Valuing a Deal (Student Spreadsheet Supplement)." Harvard Business School Spreadsheet Supplement 623-715, June 2023.
      • April 2023
      • Case

      Elliott Management: Capital Allocation in Biopharma

      By: Amitabh Chandra, Paul Clancy and Lauren Gunasti
      The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an...  View Details
      Keywords: Finance; Strategy; Capital Allocation; Biopharmaceutical Industry; Shareholder Activism
      Citation
      Educators
      Purchase
      Related
      Chandra, Amitabh, Paul Clancy, and Lauren Gunasti. "Elliott Management: Capital Allocation in Biopharma." Harvard Business School Case 623-045, April 2023.
      • January 2023
      • Case

      Vertex and the Cure for Type 1 Diabetes

      By: Amitabh Chandra, William J Anderson and Silvia Mare
      Keywords: Biotechnology Industry
      Citation
      Educators
      Related
      Chandra, Amitabh, William J Anderson, and Silvia Mare. "Vertex and the Cure for Type 1 Diabetes ." Harvard Business School Case 623-053, January 2023.
      • 2023
      • Working Paper

      Achieving Universal Health Insurance Coverage in the United States: Addressing Market Failures or Providing a Social Floor?

      By: Katherine Baicker, Amitabh Chandra and Mark Shepard
      The United States spends substantially more on health care than most developed countries, yet leaves a greater share of the population uninsured. We suggest that incremental insurance expansions focused on addressing market failures will propagate inefficiencies and...  View Details
      Keywords: Public Sector; Insurance; Health Care and Treatment; Policy; Innovation and Invention
      Citation
      Purchase
      Related
      Baicker, Katherine, Amitabh Chandra, and Mark Shepard. "Achieving Universal Health Insurance Coverage in the United States: Addressing Market Failures or Providing a Social Floor?" NBER Working Paper Series, No. 30854, January 2023.
      • 2022
      • Working Paper

      Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation

      By: Amitabh Chandra, Jennifer Kao, Kathleen Miller and Ariel D. Stern
      Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA’s Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can use new policy to...  View Details
      Keywords: Research and Development; Governing Rules, Regulations, and Reforms; Product Development
      Citation
      Find at Harvard
      Purchase
      Related
      Chandra, Amitabh, Jennifer Kao, Kathleen Miller, and Ariel D. Stern. "Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation." NBER Working Paper Series, No. 30712, December 2022.
      • July 2022
      • Supplement

      Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A (Spreadsheet Supplement)

      By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
      Citation
      Purchase
      Related
      Chandra, Amitabh, Paul Clancy, and Craig Garthwaite. "Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A (Spreadsheet Supplement)." Harvard Business School Spreadsheet Supplement 623-701, July 2022.
      • July 2022
      • Teaching Note

      Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A

      By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
      Teaching Note for HBS Case No. 622-075.  View Details
      Citation
      Purchase
      Related
      Chandra, Amitabh, Paul Clancy, and Craig Garthwaite. "Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A." Harvard Business School Teaching Note 623-014, July 2022.
      • January 2022 (Revised July 2022)
      • Case

      Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A

      By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
      Citation
      Educators
      Purchase
      Related
      Chandra, Amitabh, Paul Clancy, and Craig Garthwaite. "Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A." Harvard Business School Case 622-075, January 2022. (Revised July 2022.)
      • December 2021 (Revised February 2023)
      • Teaching Note

      Value-Based Insurance Design at Onex

      By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal
      Teaching Note for HBS Case No. 921-023.  View Details
      Citation
      Purchase
      Related
      Schwartzstein, Joshua, Amitabh Chandra, and Amram Migdal. "Value-Based Insurance Design at Onex." Harvard Business School Teaching Note 922-030, December 2021. (Revised February 2023.)
      • Article

      Supporting Value-Based Health Care—Aligning Financial and Legal Accountability

      By: Mark M. Zaki, Anupam B. Jena and Amitabh Chandra
      U.S. health care payment and delivery-system reforms have focused on improving care by making organizations accountable for outcomes, quality, and costs. Payers have supported the implementation of accountable care organizations (ACOs), bundled-payment models, and...  View Details
      Keywords: Value-based Health Care; Accountability; Health Care and Treatment; United States
      Citation
      Find at Harvard
      Register to Read
      Related
      Zaki, Mark M., Anupam B. Jena, and Amitabh Chandra. "Supporting Value-Based Health Care—Aligning Financial and Legal Accountability." New England Journal of Medicine 385, no. 11 (September 9, 2021): 965–967.
      • June 2021
      • Case

      Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (A)

      By: Amitabh Chandra and Spencer Lee-Rey
      Citation
      Educators
      Purchase
      Related
      Chandra, Amitabh, and Spencer Lee-Rey. "Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (A)." Harvard Business School Case 621-110, June 2021.
      • June 2021
      • Supplement

      Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)

      By: Amitabh Chandra and Spencer Lee-Rey
      Citation
      Purchase
      Related
      Chandra, Amitabh, and Spencer Lee-Rey. "Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)." Harvard Business School Supplement 621-111, June 2021.
      • 2021
      • Working Paper

      Regulatory Approval and Expanded Market Size

      By: Benjamin Berger, Amitabh Chandra and Craig Garthwaite
      Regulatory review of new medicines is often viewed as a hindrance to innovation by increasing the hurdle to bring products to market. However, a more complete accounting of regulation must also account for its potential market expanding effects through quality...  View Details
      Keywords: New Medicines; Regulatory Approval; Health Care and Treatment; Research and Development; Governing Rules, Regulations, and Reforms; Markets; Expansion; Pharmaceutical Industry
      Citation
      Find at Harvard
      Read Now
      Related
      Berger, Benjamin, Amitabh Chandra, and Craig Garthwaite. "Regulatory Approval and Expanded Market Size." NBER Working Paper Series, No. 28889, June 2021.
      • 2021
      • Working Paper

      The Great Unequalizer: Initial Health Effects of COVID-19 in the United States

      By: Marcella Alsan, Amitabh Chandra and Kosali I. Simon
      We measure inequities from the COVID-19 pandemic on mortality and hospitalizations in the United States during the early months of the outbreak. We discuss challenges in measuring health outcomes and health inequality, some of which are specific to COVID-19 and others...  View Details
      Keywords: COVID-19; Health Inequality; Health Pandemics; Demographics; Equality and Inequality
      Citation
      Find at Harvard
      Read Now
      Related
      Alsan, Marcella, Amitabh Chandra, and Kosali I. Simon. "The Great Unequalizer: Initial Health Effects of COVID-19 in the United States." NBER Working Paper Series, No. 28958, June 2021.
      • May 2021
      • Case

      The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease

      By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
      This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory...  View Details
      Keywords: Innovation and Invention; Strategy; Business or Company Management; Society; Health; Public Administration Industry; Health Industry; United States
      Citation
      Educators
      Purchase
      Related
      Chandra, Amitabh, Spencer Lee-Rey, and Caroline Marra. "The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease." Harvard Business School Case 621-112, May 2021.
      • 2021
      • Working Paper

      The Health Costs of Cost-Sharing

      By: Amitabh Chandra, Evan Flack and Ziad Obermeyer
      We use the design of Medicare’s prescription drug benefit program to demonstrate three facts about the health consequences of cost-sharing. First, we show that an as-if-random increase of 33.6% in out-of-pocket price (11.0 percentage points (p.p.) change in...  View Details
      Keywords: Cost-sharing; Impact; Health Care and Treatment; Insurance; Health; Consumer Behavior
      Citation
      Read Now
      Related
      Chandra, Amitabh, Evan Flack, and Ziad Obermeyer. "The Health Costs of Cost-Sharing." NBER Working Paper Series, No. 28439, February 2021.
      • 1
      • 2
      • 3
      • →
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College